3SBio Stock

3SBio FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of 3SBio (1530.HK) as of Aug 13, 2026 is 107.61 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 107.07 % — a change of 0.51% (higher).

FCF Conversion

107.61 %

YoY

0.51%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of 3SBio is 2026 107.61 % . FCF Conversion Rate (FCF/EBITDA) of 3SBio was 2025 107.07 % . It decreases by 0.51% higher compared to the previous year.
Access this data via the Eulerpool API

3SBio Stock analysis

What does 3SBio do? 3SBio Inc. is a biopharmaceutical company from China that specializes in the research, development, manufacturing, and marketing of biological products. It was founded in 1993 in Shenyang, a city in northeast China, and its headquarters are now in Beijing. 3SBio's business model is based on the development and manufacturing of biopharmaceuticals that are used to treat cancer, autoimmune diseases, and other serious illnesses. The company focuses on biological medicines such as proteins, antibodies, and peptides that are produced using genetic technology. 3SBio operates a wide range of business sectors, including the manufacturing and sale of biopharmaceutical products, the manufacturing and sale of generics and biosimilar products, and research and development in the biotechnology field. The company also has several subsidiaries and joint ventures, including 3SBio International Holding, Sunshine Guojian Pharmaceutical, and Target Pharma. A well-known product of 3SBio is erythropoietin (EPO), which is used in the treatment of anemia. The company also has a portfolio of other biopharmaceutical products that are used to treat cancer, autoimmune diseases, and other serious illnesses. The history of 3SBio goes back to 1993 when it was founded as Shenyang Sunshine Pharmaceutical. In 2001, the company was renamed "Shenyang Sunshine Pharmaceutical Co. Ltd. 3S Bio" and focused on biological therapy. In 2007, the company successfully listed on the Hong Kong Stock Exchange and received the name 3SBio. In 2013, the company was privatized and acquired by a consortium of Chinese investment companies. 3SBio has a strong presence in China and is also expanding into international markets. The company has distribution partnerships in Asia, Europe, and North America, and plans to enter more markets. Overall, 3SBio is a leading company in China in the field of biopharmaceuticals that focuses on the treatment of serious illnesses. The company aims to be a leader in research and development, as well as in the manufacturing and sale of innovative products, and to expand its presence in global markets. 3SBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 3SBio stock

FCF Conversion Rate (FCF/EBITDA) of 3SBio is 107.61 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of 3SBio changed from 107.07 % to 107.61 %, representing a 0.51% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) 3SBio since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s 3SBio with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — 3SBio

All Key Metrics — 3SBio